Related News Items
Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index
Mon, 21 May 2012 03:30:00 -0700
Pacira Pharmaceuticals, Inc. today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index® effective today. The National B
Read More...
New York Biotechnology Association to Honor Regeneron Founders as Business Leaders of the Year
Fri, 18 May 2012 05:45:00 -0700
New York Biotechnology Association , the voice of New York State’s bioscience industry, today announced that the 2012 honorees of the Association’s annual leadership awards will be the leaders of Regeneron Pharmaceuticals, New York’s largest biotechnology company: Dr.
Read More...
Spectrum Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Tue, 08 May 2012 04:00:00 -0700
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company’s business strategy will be given at the Bank of America Merrill Lynch 2012 Health Care Conference being held at Encore at the Wynn Hotel in Las Vegas, Nevada.
Read More...
Infinity Added to NASDAQ Biotechnology Index
Tue, 15 May 2012 05:00:00 -0700
Infinity Pharmaceuticals, Inc. today announced that the company will be added to the NASDAQ Biotechnology Index® . The semi-annual re-ranking of the index will
Read More...
Spectrum Pharmaceuticals to Present at the Deutsche Bank 37th Annual Health Care Conference
Tue, 01 May 2012 04:00:00 -0700
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today that an overview of the Company’s business strategy will be given at the 37th Annual Deutsche Bank Health Care Conference being held at The InterContinental Boston in Boston, Massachusetts.
Read More...
Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of ...
Thu, 24 May 2012 16:06:00 -0700
Spectrum Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos for $1.82 per share in cash, without interest and less any applicable withholding taxes, plus one Contingent Value Right, which entitles Allos ...
Read More...
Spectrum Pharmaceuticals Commences Phase 2 Study of ZEVALIN® in Combination with the Redox Modulating Agent Motexafin ...
Thu, 17 May 2012 04:00:00 -0700
Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN® Injection for intravenous use + rituximab in combination with motexafin gadolinium in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin ...
Read More...
BIO Lauds Senate Passage of User Fee Package
Thu, 24 May 2012 14:06:00 -0700
Biotechnology Industry Organization President and CEO Jim Greenwood issued the following statement in support of the U.S. Senate’s approval of the Food and Drug Administratio
Read More...
Panel of Top Industry Executives to Discuss Biotech and Big Pharma – What’s Next? – 2012 BIO International Convention ...
Wed, 16 May 2012 13:54:00 -0700
The Biotechnology Industry Organization announced today that a panel of top industry executives will discuss where biotech will be in the next ten years and how the pharmaceutical industry landscape is changing.
Read More...
Tonix Pharmaceuticals CEO Interviewed on CEOLive.TV
Wed, 23 May 2012 05:00:00 -0700
Tonix Pharmaceuticals Holding Corp. , a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system , including fibromyalgia syndrome and post-traumatic stress disorder , today announced that Chief Executive Officer Seth Lederman, MD, was interviewed by CEOLive.TV.
Read More...